Immunity Pharma

Company Overview

Snapshot

Founded in March 2007, Immunity Pharma operates with 1–10 employees, focusing on developing therapies for neurodegenerative diseases. The company's lead drug, IPL344, is currently in an open-label, phase 1/2a clinical trial for ALS patients, demonstrating significant progress in its therapeutic development.

Business overview

Immunity Pharma (IPL) is a Health Tech & Life Sciences company specializing in the development of therapies for neurodegenerative diseases, with an initial focus on Amyotrophic Lateral Sclerosis (ALS). The company's core technology involves peptide-based drugs that stimulate therapeutic cell-signaling processes, aiming to mitigate disease progression by reducing inflammation and programmed cell death. Immunity Pharma serves the pharmaceutical market, particularly targeting the treatment of degenerative diseases.

Strategic signal

In September 2020, Immunity Pharma announced promising interim results from its Phase 1/2a study of IPL344 in ALS patients. This milestone is a significant validation of the company's therapeutic approach and signals potential efficacy in a challenging disease area, which could attract further investment and accelerate clinical development.

Company Intelligence Q&A

What is Immunity Pharma's primary focus?

Immunity Pharma primarily focuses on developing therapies for neurodegenerative diseases, with an initial emphasis on Amyotrophic Lateral Sclerosis (ALS).

What is IPL344?

IPL344 is Immunity Pharma's lead drug candidate, a peptide designed to stimulate therapeutic cell-signaling processes to mitigate disease progression in neurodegenerative conditions like ALS.

What is the current development stage of IPL344?

IPL344 is currently entering an open-label, phase-1/2a clinical trial with ALS patients.

When did Immunity Pharma announce interim results for its IPL344 study?

In September 2020, Immunity Pharma announced promising interim results of its Phase 1/2a study with IPL344 in ALS.

Where did the IPL344 drug originate?

IPL344 originated from the research laboratory of Professor Irun Cohen at the Weizmann Institute of Science in Israel.